```
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:37:39 ON 19 SEP 2007

=> fil reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 11:37:50 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   18 SEP 2007  HIGHEST RN 947490-11-1
DICTIONARY FILE UPDATES:  18 SEP 2007  HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10584222-2 no hydroxy.str
```



chain nodes :
19 20 21 22 23 24 25 26 27
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
chain bonds :
2-21 5-22 9-27 12-26 13-25 16-19 17-20 22-23 23-24 24-25 26-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-11 7-18 8-9 8-18 9-10 10-11 12-13 12-17 13-14 14-15 15-16 16-17
exact/norm bonds :
12-13 12-17 13-14 14-15 15-16 16-17 16-19
exact bonds :
2-21 5-22 9-27 12-26 13-25 17-20 22-23 23-24 24-25 26-27
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-11 7-18 8-9 8-18 9-10 10-11

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 11:38:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 12 TO ITERATE

100.0% PROCESSED 12 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 33 TO 447
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> d l2 -12

L2 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2007 ACS on STN
RN 221105-43-7 REGISTRY
ED Entered STN: 08 Apr 1999
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[methyl(3-pyridinylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)
MF C20 H20 Br Cl N4 O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (221105-44-8)



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2007 ACS on STN
RN 171661-81-7 REGISTRY
ED Entered STN: 22 Dec 1995

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-[(3-pyridinylmethyl)amino]-, (S)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H18 Br Cl N4 O3
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> f caplus medline
0 CAPLUS
0 MEDLINE
L3 0 CAPLUS MEDLINE
(CAPLUS(W)MEDLINE)

=> fil caplus medline

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.15	15.36

FILE 'CAPLUS' ENTERED AT 11:39:38 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'MEDLINE' ENTERED AT 11:39:38 ON 19 SEP 2007

=> s l2
L4 2 L2

=> d l4 ibib abs hitstr 1-2

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:184137 CAPLUS Full-text
DOCUMENT NUMBER: 130:227734
TITLE: Neovascularization promoters and neovascularization potentiators
INVENTOR(S): Egi, Yasuhiro; Kido, Hideaki; Hayashi, Kazutaka; Kubo,

Yoshiji; Nakamura, Norifumi
PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan;
Nissan Chemical Industries, Ltd.
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9911268	A1	19990311	WO 1998-JP3820	19980826
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2301852	A1	19990311	CA 1998-2301852	19980826
CA 2301852	C	20070710		
AU 9888862	A	19990322	AU 1998-88862	19980826
EP 1025847	A1	20000809	EP 1998-940584	19980826
EP 1025847	B1	20051026		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 307584	T	20051115	AT 1998-940584	19980826
ES 2247716	T3	20060301	ES 1998-940584	19980826
TW 490303	B	20020611	TW 1998-87114142	19980827
US 6284758	B1	20010904	US 2000-486327	20000225

PRIORITY APPLN. INFO.: JP 1997-232644 A 19970828
WO 1998-JP3820 W 19980826

OTHER SOURCE(S): MARPAT 130:227734
GI



I

AB The invention relates to neovascularization promoters and neovascularization potentiators, containing as the active ingredient pyridazinone compds. represented by general formula (I) [R1-3 = H or lower alkyl; X = halo, cyano or H : Y = halo, trifluoromeyhl or H; A = (un)substituted C1-8 alkylene] or pharmacol. acceptable salts thereof wherein each symbol is as defined in the specification. The pyridazinone compds. and pharmacol. acceptable salts thereof have the effects of promoting neovascularization and potentiating the drugs having these effects, which makes them useful as neovascularization promoters and neovascularization potentiators.

IT 221105-43-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neovascularization promoters and neovascularization potentiators)
RN 221105-43-7 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[methyl(3-pyridinylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:992456 CAPLUS Full-text
DOCUMENT NUMBER: 124:55968
TITLE: Preparation of pyridazinone derivatives having potent antithrombocytic activity
INVENTOR(S): Tanikawa, Keizo; Matsumoto, Takashi; Matsumoto, Hiroo; Tsuruzoe, Nobutomo; Nakabeppu, Hitoshi
PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9519969	A1	19950727	WO 1995-JP69	19950124
W: AU, CA, CN, CZ, FI, HU, KR, MX, NO, NZ, RO, RU, SI, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2181901	A1	19950727	CA 1995-2181901	19950124
CA 2181901	C	20050913		
AU 9514663	A	19950808	AU 1995-14663	19950124
EP 742211	A1	19961113	EP 1995-906505	19950124
EP 742211	B1	20000510		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, PT, SE				
CN 1138852	A	19961225	CN 1995-191304	19950124
CN 1049892	B	20000301		
HU 74742	A2	19970228	HU 1996-2021	19950124
HU 223963	B1	20050329		

AT 192741	T	20000515	AT 1995-906505		19950124
ES 2147841	T3	20001001	ES 1995-906505		19950124
PT 742211	T	20001031	PT 1995-906505		19950124
JP 07252237	A	19951003	JP 1995-9398		19950125
JP 3666042	B2	20050629			
TW 420665	B	20010201	TW 1995-84100797		19950127
US 5750523	A	19980512	US 1996-676227		19960723
FI 9602957	A	19960724	FI 1996-2957		19960724
FI 112214	B1	20031114			
NO 9603095	A	19960924	NO 1996-3095		19960724
NO 307965	B1	20000626			
US 5856327	A	19990105	US 1997-936600		19970924
PRIORITY APPLN. INFO.:			JP 1994-6541	A	19940125
			WO 1995-JP69	W	19950124
			US 1996-676227	A3	19960723

OTHER SOURCE(S): CASREACT 124:55968; MARPAT 124:55968

GI



I



II

AB Pyridazinone derivs. represented by general formula [I; R = H, C1-4 alkyl; X = H, Cl, Br; Ar = pyridyl, Ph substituted by OR1 (wherein R1 = H or C1-4 alkyl) and a group selected from H, halo, or C1-4 alkyl or a group selected from OH or C1-4 alkoxy; Y = C1-8 alkylene, one of its C atom being substituted by one OR1 group; Z1, Z2 = H, halo, C1-4 alkyl, OR1 (R1 being as defined above)], which have a broad spectrum of blood platelet aggregation inhibition with high selectivity and reduced side effects (e.g. headache, heaviness of head, hypotension, and palpitation) and are safely used as the active ingredient of a preventive or remedy for various thrombotic diseases, are prepared Thus, a mixture of 1.50 g 4,5-dibromo-6-[3-(4-chlorophenyl)-3-hydroxypropyloxy]-3(2H)-pyridazinone, 1.48 g 3-picolylamine, 45 mL MeOH, and 5 mL H2O was refluxed with stirring overnight to give 1.05 g of the title compound (II; R2 = OH). This compound in vitro inhibited the ADP- and collagen-induced blood platelet aggregation of rabbit platelet rich plasma with IC50 of 0.23 and 0.099 μM, resp. It in vitro showed weaker vasodilating activity (EC50 of 1.3 μM) than the known compound II.HCl (R2 = H) (EC50 of 0.4 μM) in an assay of inhibiting the phenylephrine-induced contraction of rabbit thoracic aorta rings. A tablet and a capsule formulation containing II (R2 = OH) were described.

IT 171661-81-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridazinone derivs. having potent antithrombocytic activity)

RN 171661-81-7 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-[(3-

pyridinylmethyl)amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	12.77	28.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:42:35 ON 19 SEP 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAGXP1614

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS, MEDLINE' AT 13:35:23 ON 19 SEP 2007
FILE 'CAPLUS' ENTERED AT 13:35:23 ON 19 SEP 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'MEDLINE' ENTERED AT 13:35:23 ON 19 SEP 2007

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	12.77	28.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

=> d hist

(FILE 'HOME' ENTERED AT 11:37:39 ON 19 SEP 2007)

```
     FILE 'REGISTRY' ENTERED AT 11:37:50 ON 19 SEP 2007
L1                STRUCTURE UPLOADED
L2             2 S L1
L3             0 F CAPLUS MEDLINE

     FILE 'CAPLUS, MEDLINE' ENTERED AT 11:39:38 ON 19 SEP 2007
L4             2 S L2

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    12.77      28.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -1.56      -1:56

FILE 'REGISTRY' ENTERED AT 13:35:37 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   18 SEP 2007  HIGHEST RN 947490-11-1
DICTIONARY FILE UPDATES:  18 SEP 2007  HIGHEST RN 947490-11-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s l1 full
FULL SEARCH INITIATED 13:35:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      189 TO ITERATE

100.0% PROCESSED      189 ITERATIONS                          21 ANSWERS
SEARCH TIME: 00.00.01

L5            21 SEA SSS FUL L1

=> fil caplus medline
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   172.10     200.23

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -1.56
```

```
FILE 'CAPLUS' ENTERED AT 13:35:59 ON 19 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 13:35:59 ON 19 SEP 2007

=> s l5
L6          23 L5

=> d scan

L6    23 ANSWERS   CAPLUS  COPYRIGHT 2007 ACS on STN
IC    ICM  A61K031-496
      ICS  A61K045-06; A61P015-00
CC    1-11 (Pharmacology)
      Section cross-reference(s): 2, 63
TI    New pharmaceutical compositions for the treatment of sexual disorders
ST    flibanserin combination drug delivery sexual disorder
IT    Dopamine antagonists
         (D4; new pharmaceutical compns. for treatment of sexual disorders)
IT    Behavior
      Mental activity
         (arousal; new pharmaceutical compns. for treatment of sexual disorders)
IT    Sexual disorders
         (impotence; new pharmaceutical compns. for treatment of sexual
         disorders)
IT    Sexual behavior
         (libido, loss of or disturbance; new pharmaceutical compns. for
         treatment of sexual disorders)
IT    Combination chemotherapy
      Drug delivery systems
      Enantiomers
      Human
      Sexual disorders
      α-Adrenoceptor antagonists
         (new pharmaceutical compns. for treatment of sexual disorders)
IT    Androgens
      Estrogens
      Peptides, biological studies
      RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
      (Biological study); USES (Uses)
         (new pharmaceutical compns. for treatment of sexual disorders)
IT    Solvates
         (pharmaceutically acceptable; new pharmaceutical compns. for treatment
         of sexual disorders)
IT    Hydrates
      RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
      (Biological study); USES (Uses)
         (pharmaceutically acceptable; new pharmaceutical compns. for treatment
         of sexual disorders)
IT    Ovarian cycle
         (premenstrual syndrome; new pharmaceutical compns. for treatment of
         sexual disorders)
IT    Androgen receptors
      Estrogen receptors
      RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
      (Biological study); USES (Uses)
         (selective modulators of; new pharmaceutical compns. for treatment of
         sexual disorders)
```

IT Pain
(sexual; new pharmaceutical compns. for treatment of sexual disorders)
IT 5-HT receptors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(type 5-HT2A, antagonists; new pharmaceutical compns. for treatment of sexual disorders)
IT 5-HT receptors
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(type 5-HT2C, antagonists; new pharmaceutical compns. for treatment of sexual disorders)
IT 105299-80-7, HMP 12
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(HMP 12; new pharmaceutical compns. for treatment of sexual disorders)
IT 200195-01-3, CI 1030
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PD 172760; new pharmaceutical compns. for treatment of sexual disorders)
IT 192324-89-3, SCH 71450
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SCH 71450; new pharmaceutical compns. for treatment of sexual disorders)
IT 128908-32-7, Melanocortin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(agonists; new pharmaceutical compns. for treatment of sexual disorders)
IT 10102-43-9, Nitric oxide, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(donors; new pharmaceutical compns. for treatment of sexual disorders)
IT 7665-99-8, Cgmp
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(new pharmaceutical compns. for treatment of sexual disorders)
IT 50-27-1, Estriol 50-28-2, Estradiol, biological studies 50-60-2, Phentolamine 52-01-7, Spironolactone 53-16-7, Estrone, biological studies 53-39-4, Oxandrolone 53-41-8, Androsterone 53-43-0, Dehydroepiandrosterone 55-63-0, Nitroglycerin 56-53-1, Diethylstilbestrol 57-63-6, 17α-Ethinylestradiol 57-91-0, 17α-Estradiol 58-18-4, Methyl Testosterone 58-19-5, Dromostanolone 58-22-0, Testosterone 58-22-0D, Testosterone, esters 58-74-2, Papaverine 62-90-8, Nandrolone phenpropionate 63-05-8, Androstenedione 65-28-1, Phentolamine mesylate 72-33-3, Mestranol 76-43-7, Fluoxymesterone 147-27-3, Dioxyline 152-43-2, Quinestrol 360-70-3, Nandrolone decanoate 427-51-0, Cyproterone acetate 434-07-1, Oxymetholone 481-97-0, Estrone sulfate 486-47-5, Ethaverine 514-68-1, Estriol succinate 521-12-0, Dromostanolone propionate 521-17-5, Androstenediol 521-18-6, 4-Dihydrotestosterone 521-18-6D, 4-DihydroTestosterone, esters 745-65-3, Alprostadil 745-65-3D, ProstaglandinE1, agonists 901-93-9, EStrone acetate 911-45-5, Clomiphene 912-57-2, Nandrolone cyclohexane-propionate 965-90-2, Ethylestrenol 968-93-4, Testolactone 1099-87-2, Sodium dehydroepiandrosterone sulfate 1164-95-0, Androsterone acetate 1175-12-8, Androstenediol-17-benzoate 1474-55-1, Nandrolone benzoate 1639-43-6, Androstenediol-3-acetate 1845-11-0, Nafoxidine 2099-26-5, Androstenediol-3,17-Diacetate 2565-01-7, Nantenine 5630-53-5, Tibolone

5779-47-5, Ethynylestradiol 3-acetate 5934-04-3, Ethynylestradiol 3-benzoate 5937-72-4, Androstenediol-17-acetate 5953-63-9, Androstenediol-3-acetate-17-benzoate 5953-68-4, Androsterone propionate 5953-69-5, Androsterone benzoate 7280-37-7, Piperazine estrone sulfate 7642-64-0, Nandrolone furylpropionate 10418-03-8, Stanozolol 10540-29-1, Tamoxifen 15574-96-6, Pizotifen 18016-80-3, Lisuride 18470-94-5, Nandrolone cyclohexanecarboxylate 19216-56-9, Prazosin 21102-95-4, BMY-7378 25447-66-9, α-Dihydroergocryptin 25614-03-3, Bromocriptin 28014-46-2, Polyestrol phosphate 30519-91-6 34661-75-1, Urapidil 34816-55-2, Moxestrol 34911-55-2, Bupropion 36505-84-7, Buspirone 37221-79-7, VIP 37686-84-3, Terguride 38304-91-5, Minoxidil 52806-53-8, Hydroxyflutamide 54910-89-3, Fluoxetine 57149-07-2, Naftopidil 59798-73-1, Enilospirone 63619-84-1, Trioxifene 63676-25-5, LY117018 64318-79-2, Gemeprost 65576-45-6, Asenapine 66104-22-1, Pergolide 66327-51-3, Furazlocillin 70006-24-5, ABT-724 70667-26-4, Ornoprostil 72135-20-7, LUR-2366 74050-98-9, Ketanserin 74397-12-9, Limaprost 74938-11-7, 7-OH-DPAT 75272-39-8, Nemonapride 75558-90-6, Amperozide 81409-90-7, Cabergoline 82413-20-5, Droloxifene 82900-57-0, BP 554 83366-66-9, Nefazodone 83455-48-5, Bromerguride 83928-76-1, Gepirone 84449-90-1, Raloxifene 84449-90-1D, Raloxifene, 2-alkyl- derivs. 84449-90-1D, Raloxifene, 2-cycloalkyl- derivs. 84449-90-1D, Raloxifene, 4'-halo- derivs. 84449-90-1D, Raloxifene, derivs. 85273-96-7, ICI-169369 86111-26-4, Zindoxifene 87051-43-2, Ritanserin 87760-53-0, Tandospirone 89778-26-7, Toremifene 90357-06-5, Bicalutamide 90494-79-4, Xaliproden hydrochloride 91374-21-9, Ropinirole 95847-70-4, Ipsapirone 96478-43-2, Irindalone 98007-99-9 98206-10-1, Flesinoxan 98216-44-5, LY 175644 98224-03-4, Eltoprazine 98330-05-3, Anpirtoline 98770-54-8, Bay-r-1531 100746-36-9, CGS-18102A 101626-70-4, Talipexole 102771-12-0, Nerisopam 102908-59-8, Binospirone 104054-27-5, MPV1248 104632-26-0, Pramipexole 105565-56-8, BMS-181100 106266-06-2, Risperidone 107008-28-6, RU 24969 107736-98-1, Umespirone 109028-10-6, CGS-12066B 111635-21-3, PM 1000 112192-04-8, Roxindole 113777-33-6, MDL-72832 114298-18-9, Zalospirone 114943-19-0, LY 178210 115464-77-2, Elopiprazole 115994-31-5, LY 228729 116057-75-1, Idoxifene 118716-02-2, CGP 50281 119978-03-9, FG5803 120444-71-5, Deramciclane 121588-75-8, Amesergide 123547-30-8, RWJ-25730 125926-17-2, Sarpogrelate 127266-56-2, Adatanserin 127625-29-0, Fananserin 128185-43-3 129029-23-8, Ocaperidone 129301-34-4, U 67413B 129453-61-8, Fulvestrant 129592-83-2, AP 159 129612-87-9, Miproxifene 129722-12-9, Aripiprazole 130132-97-7, SL 870765 130579-75-8, EPlivanserin 131112-58-8, SUN-8399 131540-60-8, HP 236 132449-45-7, E 4414 132449-46-8, Lesopitron 132501-12-3, WY 48723 132539-06-1, Olanzapine 132873-34-8, LY-274601 132873-35-9, LY 274600 132874-73-8, U-86170 132895-75-1, RS-30199-193 133109-86-1, EMD-56551 133454-47-4, ILoperidone 134208-18-7, Mazapertine succinate 135721-98-1, S-14506 135722-27-9, S-14671 137275-80-0, MKC-242 137328-52-0, LY215840 137578-34-8, U 86192A 138112-76-2, Agomelatine 138298-79-0, Alnespirone 139145-27-0 139290-65-6, M100907 139755-83-2, Sildenafil 140221-50-7, LY 41 140694-43-5, TY 11223 141318-62-9, LY 293284 141474-54-6, SDZSER082 142494-12-0, Org 13011 143797-62-0, SB200646A 144980-29-0, Repinotan 145969-30-8, OPC-14523 146479-45-0, BMS-181101 146939-27-7, Ziprasidone 146998-34-7, S-15535 147145-16-2, U-93385 147359-76-0, Flibanserin hydrochloride 147676-53-7 147676-63-9 148408-65-5, Sunepitron 149494-37-1, Ebalzotan 149654-41-1, U-92016A 149859-10-9, JL 13 150450-07-0 150452-19-0 150527-23-4, FG 5893 150527-35-8, FG 5865 150527-36-9, FG 5974 152352-44-8, ZD 3638 153415-44-2, LEK 8804 153607-45-5, S-15931 155289-31-9, 1192U90 156337-32-5, L 741742 156896-33-2, LY 301317 157622-55-4, S-14297 158942-04-2, SB-206553 158985-00-3, L

745870 159650-30-3, MDL-73975 160161-67-1, LEK-8829 160418-78-0, BIMG80 161178-07-0, Lubazodone 163465-69-8, CP 291952 163521-12-8, Vilazodone 167298-74-0, Sch-51866 167298-97-7 167933-07-5, Flibanserin 169167-86-6, S-16924 169451-66-5, YM-43611 170856-41-4, PNU-96415E 170858-33-0, Sonepiprazole 171596-29-5, Tadalafil 175737-59-4, 6-(4-Hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol 176219-00-4, B 20991 177975-08-5, EMD-77697 178308-66-2, E 4010 178930-30-8, CP 293019 178993-08-3, B-8805-033 179333-18-7 179386-43-7, Sumanirole 179556-82-2, U-101958
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(new pharmaceutical compns. for treatment of sexual disorders)

IT 179756-85-5, Eptapirone 180915-78-0 180915-84-8 180915-86-0 180916-14-7 180916-15-8 180916-16-9, Lasofoxifene 181629-93-6, SB228357 181632-25-7, SB242084 182133-25-1, Arzoxifene 182415-09-4, SUN N4057 183070-26-0, FG 5938 183140-97-8 183849-43-6, Abaperidone 183949-64-6, NRA-0045 184147-55-5 185376-97-0, RS-102221 185515-24-6, S-18126 188433-71-8, YM 50001 189003-92-7, SL650472 189152-50-9, PD 158771 189691-06-3, PT-141 190508-50-0, AT1015 190670-74-7, EGIS9933 193074-55-4, REC-15/2615 193274-89-4 194147-90-5 196965-14-7, SB221284 198481-32-2, Bazedoxifene 200940-22-3, SB243213 202075-96-5, SDZ-MAR 327 202754-51-6, A 74283 204718-47-8, NRA-0160 204718-55-8, NRA-0215 204992-09-6, Netamiftide 206434-76-6 207277-37-0, RGH 1756 208110-64-9, F-13640 210688-71-4, PD 172938 210751-39-6, LY 367265 215297-27-1 219907-10-5, VN 2222 220941-93-5, CP 226269 221332-70-3, QF 2004B 223502-85-0, SSR-181507 224157-99-7 224785-90-4, Vardenafil 228579-02-0, LB 50016 230635-61-7, trans-2,3-Dihydroraloxifene 240404-10-8, QF 0510B 244276-65-1, NRA-0562 246517-66-8, BTS 79018 247568-68-9, FR226807 247580-98-9 247582-13-4 252021-89-9, NGB 4420 252231-68-8 252951-59-0, NCX-911 253877-49-5, Ro-62-4599 257864-13-4, AP 521 257864-15-6, AZ 16596 257864-37-2, FCE 23892 257864-38-3, LY 315535 257864-39-4, S 215521 257864-47-4, EMD 67478 269718-83-4, SLV-308 274682-89-2, Ro 27-3225 319427-14-0, BAY 38-9456 334826-98-1 334827-47-3 334827-59-7 335077-64-0 335077-70-8 344454-52-0, Org 38457 344454-70-2, EGIS 8465 350992-10-8, Bifeprunox 351862-32-3, Sarizotan 369618-20-2, S 23751 415916-57-3, E 8010 415916-78-8, BAY 38-3045 432493-87-3, LGD 2226 441351-22-0, Lu 35-138 441351-27-5, Balaperidone 443144-27-2, EMD281014 464213-10-3, SLV 319 496921-73-4, NEO 376 510719-07-0 574001-66-4, MCL-0129 577975-68-9, QF 1004B 666702-53-0 666822-52-2, LGD 1331 695184-57-7, BMS 181970 695185-70-7, SR 59026 695185-73-0, R 137696 706782-28-7, ACP 103 799841-02-4, FR 229934 843660-39-9, SLV 314 868828-81-3, Pyrido[3,2-g]quinolin-2(1H)-one 868852-83-9, PG 917 868852-86-2, NMI 775 868852-93-1, Sch 444877 868852-94-2, WAY 100012 868852-97-5, BW 1205U90 868853-09-2, HAT 90B 868853-10-5 868853-13-8, RGH 1757 868853-16-1, CL 870801 868853-18-3, CP 110330 868853-19-4, CP 146662 868853-21-8, OSU 191 868854-96-0, S 213571 868855-08-7, EMR 62218 868855-09-8, LU 31-130 868855-11-2, EGIS 10037 868855-12-3, R 107500 868855-13-4, S 35120 868855-15-6, GMC 283 868855-20-3, GMC 306 868855-25-8, GMC 6139 868855-26-9, IT 657 868855-27-0, Ro 60-0946 868855-28-1, Ro 60-0759 868855-29-2, RP 71602 868855-30-5, S 35031 868855-31-6, S 17828 868855-32-7, S 21357-1 868855-33-8, TY 12283 868855-34-9, MDL 814608A 868855-35-0, SPI 376 868855-36-1, ALX-D 4 868855-37-2, L 751852 868855-38-3, L 772620 868855-39-4, L 800892 868855-43-0, NRA 0074 868855-44-1, NRA 0154 868855-45-2, NRA 0161 868855-46-3, NRA 0219 868855-47-4, NRA 0544 868855-48-5, PD 089232 868855-49-6, PD 108306 868855-50-9, PD 165167 868855-51-0, PD 167063 868855-52-1, PD 168306 868855-54-3, PD 35680 868855-55-4, PD 82011 868855-56-5, PNU 106161 868855-57-6, PNU 106675 868855-58-7, U 103073E

```
     868855-59-8, U 96415E   868855-61-2, QF 1003B
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (new pharmaceutical compns. for treatment of sexual disorders)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s neutrophil?
L7      155047 NEUTROPHIL?

=> d hist

     (FILE 'HOME' ENTERED AT 11:37:39 ON 19 SEP 2007)

     FILE 'REGISTRY' ENTERED AT 11:37:50 ON 19 SEP 2007
L1              STRUCTURE UPLOADED
L2            2 S L1
L3            0 F CAPLUS MEDLINE

     FILE 'CAPLUS, MEDLINE' ENTERED AT 11:39:38 ON 19 SEP 2007
L4            2 S L2

     FILE 'REGISTRY' ENTERED AT 13:35:37 ON 19 SEP 2007
L5           21 S L1 FULL

     FILE 'CAPLUS, MEDLINE' ENTERED AT 13:35:59 ON 19 SEP 2007
L6           23 S L5
L7       155047 S NEUTROPHIL?

=> s l6 and l7
L8           1 L6 AND L7

=> d scan

L8    1 ANSWERS   CAPLUS  COPYRIGHT 2007 ACS on STN
IC    ICM  A61K031-501
      ICS  A61P007-00; A61P011-00; C07D401-12
CC    1-12 (Pharmacology)
      Section cross-reference(s): 63
TI    Pyridazinone derivative as neutrophilia inhibitor
ST    pyridazinone deriv neutrophilia inhibitor
IT    Lung, disease
         (chronic obstructive pulmonary disease; use of pyridazinone derivative with
         neutrophilia inhibiting activity)
IT    Neutrophil
         (disease, neutrophilia; pyridazinone derivative or salts thereof
         as neutrophilia inhibitors)
IT    Acids, biological studies
      RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
         (inorg., salts; pyridazinone derivative or salts thereof as
         neutrophilia inhibitors)
IT    Blood, disease
         (neutrophilia; pyridazinone derivative or salts thereof as
         neutrophilia inhibitors)
IT    Salts, biological studies
      RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
         (organic; pyridazinone derivative or salts thereof as neutrophilia
         inhibitors)
IT    Salts, biological studies
      RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
```

```
     (Biological study); USES (Uses)
        (pyridazinone derivative or salts thereof as neutrophilia
        inhibitors)
IT   139145-27-0 139145-84-9 169202-10-2
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (pyridazinone derivative as neutrophilia inhibitor)

ALL ANSWERS HAVE BEEN SCANNED


=> s copd
L9       15064 COPD

=> d gust
'GUST' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid
in at least one of the files.  Refer to file specific help messages
or the STNGUIDE file for information on formats available in
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):end

=> d hist

     (FILE 'HOME' ENTERED AT 11:37:39 ON 19 SEP 2007)

     FILE 'REGISTRY' ENTERED AT 11:37:50 ON 19 SEP 2007
L1               STRUCTURE UPLOADED
L2             2 S L1
L3             0 F CAPLUS MEDLINE

     FILE 'CAPLUS, MEDLINE' ENTERED AT 11:39:38 ON 19 SEP 2007
L4             2 S L2

     FILE 'REGISTRY' ENTERED AT 13:35:37 ON 19 SEP 2007
L5            21 S L1 FULL

     FILE 'CAPLUS, MEDLINE' ENTERED AT 13:35:59 ON 19 SEP 2007
L6            23 S L5
L7        155047 S NEUTROPHIL?
L8             1 S L6 AND L7
L9         15064 S COPD

=> s l7 and l8
L10            1 L7 AND L8

=> s l6 and l9
L11            0 L6 AND L9

=> d l7 kwic

L7   ANSWER 1 OF 155047  CAPLUS  COPYRIGHT 2007 ACS on STN
TI   Regulation of peripheral neutrophils and CD8+ T lymphocytes in
     human Man2c1-transgenic mice
AB    . . . the transgenic mice were significantly higher than those in the wild
      type mice (P < 0.05), and the percentage of neutrophilic granulocyte was much
      higher than that in wild type control (P < 0.05). Significant increase of CD8+
      T cells was. . .
ST   transgene neutrophil CD 8 T lymphocyte human Man 2c1
```

```
=> logoff hold
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                          ENTRY    SESSION
FULL ESTIMATED COST                                        73.39     273.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                          ENTRY    SESSION
CA SUBSCRIBER PRICE                                       -17.94     -19.50

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:41:13 ON 19 SEP 2007


Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAGXP1614

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS, MEDLINE' AT 13:46:54 ON 19 SEP 2007
FILE 'CAPLUS' ENTERED AT 13:46:54 ON 19 SEP 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'MEDLINE' ENTERED AT 13:46:54 ON 19 SEP 2007

COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                          ENTRY    SESSION
FULL ESTIMATED COST                                        73.86     274.09

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                          ENTRY    SESSION
CA SUBSCRIBER PRICE                                       -17.94     -19.50

=> d hist

     (FILE 'HOME' ENTERED AT 11:37:39 ON 19 SEP 2007)

     FILE 'REGISTRY' ENTERED AT 11:37:50 ON 19 SEP 2007
L1                STRUCTURE UPLOADED
L2             2 S L1
L3             0 F CAPLUS MEDLINE

     FILE 'CAPLUS, MEDLINE' ENTERED AT 11:39:38 ON 19 SEP 2007
L4             2 S L2

     FILE 'REGISTRY' ENTERED AT 13:35:37 ON 19 SEP 2007
L5            21 S L1 FULL

     FILE 'CAPLUS, MEDLINE' ENTERED AT 13:35:59 ON 19 SEP 2007
L6            23 S L5
L7        155047 S NEUTROPHIL?
```

```
L8             1 S L6 AND L7
L9         15064 S COPD
L10            1 S L7 AND L8
L11            0 S L6 AND L9

=> d l6 ibib abs hitstr 1-23

L6   ANSWER 1 OF 23  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2007:227621  CAPLUS Full-text
DOCUMENT NUMBER:          146:259025
TITLE:                    Sustained-release preparation
INVENTOR(S):              Sato, Hirohiko; Yokoyama, Tatsuro; Kanezaki, Shota
PATENT ASSIGNEE(S):       Nissan Chemical Industries, Ltd., Japan; Taisho
                          Pharmaceutical Co., Ltd.
SOURCE:                   PCT Int. Appl., 22pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2007023729         A1    20070301    WO 2006-JP316181        20060817
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
             KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
             MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
             RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                       JP 2005-241776      A  20050823
AB   It is intended to provide a sustained-release pharmaceutical prepn. with a pH-
     independent absorbability. The sustained-release preparation is characterized
     by containing 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3- pyridylmethylamino)-
     3(2H)-pyridazinone (I) or a salt thereof as an pharmaceutically active
     ingredient and containing a hydrogel base and an organic acid. For example, a
     sustained-release tablet was formulated containing I·HCl 6, carboxyvinyl
     polymer 15, crystalline cellulose 113, citric acid 15, and Mg stearate 1 %.
IT   139145-27-0 139145-84-9
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (sustained-release prepns. containing hydrogel base and acids for
        pH-independent drug release)
RN   139145-27-0  CAPLUS
CN   3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-
     pyridinylmethyl)amino]-  (CA INDEX NAME)
```



RN 139145-84-9 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:986506 CAPLUS Full-text
DOCUMENT NUMBER: 145:342511
TITLE: New pharmaceutical compositions based on anticholinergics and PDE 5-inhibitors
INVENTOR(S): Pieper, Michael, P.
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma Gmbh & Co. KG
SOURCE: PCT Int. Appl., 28pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006094924	A2	20060914	WO 2006-EP60382	20060302
WO 2006094924	A3	20070503		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1700607	A1	20060913	EP 2005-5111	20050309
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
US 2006204450	A1	20060914	US 2006-276602	20060307
PRIORITY APPLN. INFO.:			EP 2005-5111 A	20050309

AB The present invention relates to novel pharmaceutical compns. based on anticholinergics and PDE 5-inhibitors, processes for preparing them and their use in the treatment of pulmonary hypertension. Thus an inhalable powder contained (μg/capsule): tiotropium bromide monohydrate11.25; tadalafil 5000; lactose 4988.75.

IT 139145-27-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. based on anticholinergics and PDE 5-inhibitors)

RN 139145-27-0 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



L6 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2006:167023 CAPLUS Full-text
DOCUMENT NUMBER:	144:247226
TITLE:	Use of a phosphodiesterase 5 (PDE5) inhibitor for treating and preventing hypopigmentary disorders
INVENTOR(S):	Peuker, Heidemarie
PATENT ASSIGNEE(S):	Switch Biotech A.-G., Germany
SOURCE:	PCT Int. Appl., 48 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018088	A1	20060223	WO 2005-EP7747	20050715

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1759700 A1 20070307 EP 2004-19695 20040819
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK
AU 2005274546 A1 20060223 AU 2005-274546 20050715
PRIORITY APPLN. INFO.: EP 2004-19695 A 20040819
US 2004-603069P P 20040819
WO 2005-EP7747 W 20050715

AB The invention discloses the use of PDE5 inhibitors, preferably sildenafil or tadalafil, optionally in combination with a further active ingredient, for treating and/or preventing hypopigmentary disorders.

IT 139145-27-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphodiesterase 5 inhibitor for treatment and prevention of hypopigmentary disorder)

RN 139145-27-0 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:1171443 CAPLUS Full-text
DOCUMENT NUMBER: 143:432676
TITLE: New pharmaceutical compositions for the treatment of sexual disorders
INVENTOR(S): Mendla, Klaus; Pyke, Robert; Eisenreich, Wolfram; Friedl, Thomas
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim Pharma GmbHH & Co. KG
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005102342	A1	20051103	WO 2005-EP4081	20050418

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2005235422	A1	20051103	AU 2005-235422	20050418
CA 2563743	A1	20051103	CA 2005-2563743	20050418
EP 1740181	A1	20070110	EP 2005-736586	20050418
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1946404	A	20070411	CN 2005-80012692	20050418
US 2005245539	A1	20051103	US 2005-110449	20050420
IN 2006DN06048	A	20070427	IN 2006-DN6048	20061017
MX 2006PA12059	A	20070125	MX 2006-PA12059	20061018
KR 2007014184	A	20070131	KR 2006-724443	20061121
PRIORITY APPLN. INFO.:			US 2004-564662P P	20040422
			US 2004-631800P P	20041130
			WO 2005-EP4081 W	20050418

OTHER SOURCE(S): MARPAT 143:432676

AB The invention relates to new pharmaceutical compns. for the treatment of sexual disorders and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one addnl. active ingredient for the treatment of sexual disorders and methods for the preparation thereof.

IT 139145-27-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(new pharmaceutical compns. for treatment of sexual disorders)

RN 139145-27-0 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2005:823577 CAPLUS Full-text
DOCUMENT NUMBER:	143:206431
TITLE:	Drug for inhibiting vascular intimal hyperplasia
INVENTOR(S):	Nishiyama, Hiroshi; Shudo, Norimasa; Tsuruzoe, Nobutomo
PATENT ASSIGNEE(S):	Nissan Chemical Industries, Ltd., Japan; Taisho Pharmaceutical Co., Ltd.
SOURCE:	PCT Int. Appl., 17 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	Japanese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005074938	A1	20050818	WO 2005-JP1518	20050202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005210326	A1	20050818	AU 2005-210326	20050202
CA 2553915	A1	20050818	CA 2005-2553915	20050202
EP 1714654	A1	20061025	EP 2005-709638	20050202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1905882	A	20070131	CN 2005-80001734	20050202
BR 2005007518	A	20070703	BR 2005-7518	20050202
IN 2006KN01829	A	20070511	IN 2006-KN1829	20060630
US 2007161642	A1	20070712	US 2006-585949	20060711
KR 2007029133	A	20070313	KR 2006-714583	20060720
MX 2006PA09004	A	20061020	MX 2006-PA9004	20060808
PRIORITY APPLN. INFO.:			JP 2004-32551 A	20040209
			WO 2005-JP1518 W	20050202

GI



I

AB A drug for inhibiting vascular intimal hyperplasia which is effective in the prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA) and stent placement in a blood vessel or effective in treatments for the progress thereof. The drug for inhibiting vascular intimal hyperplasia contains either a 3(2H)-pyridazinone compound represented by the formula (I): (wherein R1, R2, and R3 each independently represents hydrogen or C1-6 alkyl; X represents halogeno, cyano, or hydrogen; Y represents halogeno, trifluoromethyl, or hydrogen; and A represents optionally hydroxylated C1-8 alkylene) or a pharmacol. acceptable salt thereof.

IT 139145-27-0 169202-10-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pyridazinone derivs. and salts for inhibiting vascular intimal hyperplasia and restenosis after percutaneous transluminal coronary angioplasty)

RN 139145-27-0 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



RN 169202-10-2 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-[(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:612091 CAPLUS Full-text

DOCUMENT NUMBER: 143:126815

TITLE: Pyridazinone derivative as neutrophilia inhibitor

INVENTOR(S): Iwama, Takehisa; Tsuruzoe, Nobutomo

PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan; Taisho Pharmaceutical Co., Ltd.

SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063250	A1	20050714	WO 2004-JP19199	20041222

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

AU 2004308806	A1	20050714	AU 2004-308806		20041222
CA 2549672	A1	20050714	CA 2004-2549672		20041222
EP 1698339	A1	20060906	EP 2004-807556		20041222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU					
CN 1897952	A	20070117	CN 2004-80038158		20041222
BR 2004017200	A	20070206	BR 2004-17200		20041222
IN 2006KN01600	A	20070504	IN 2006-KN1600		20060609
US 2007117806	A1	20070524	US 2006-584222		20060623
MX 2006PA07434	A	20060809	MX 2006-PA7434		20060626
PRIORITY APPLN. INFO.:			JP 2003-433747	A	20031226
			WO 2004-JP19199	W	20041222

OTHER SOURCE(S): MARPAT 143:126815

AB Claimed is a neutrophilia inhibitor contg. a pyridazinone deriv. or pharmacol. acceptable salt thereof. The neutrophilia inhibiting activity of 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- 3(2H)-pyridazinone HCl salt (I) was demonstrated. Formulations containing I are given.

IT 139145-27-0 139145-84-9 169202-10-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyridazinone derivative as neutrophilia inhibitor)

RN 139145-27-0 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



RN 139145-84-9 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 169202-10-2 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-[(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:857442 CAPLUS Full-text
DOCUMENT NUMBER: 141:326191
TITLE: Methods for the treatment of infertility with inhibitors of phosphodiesterases (PDE) in conjunction with gonadotropins
INVENTOR(S): Palmer, Stephen S.; Mckenna, Sean D.; Arkinstall, Stephen J.; Eshkol, Aliza; Macnamee, Michael C.
PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N.V., Neth. Antilles
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087211	A2	20041014	WO 2004-US10346	20040401
WO 2004087211	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004226353	A1	20041014	AU 2004-226353	20040401
CA 2517487	A1	20041014	CA 2004-2517487	20040401
US 2004259792	A1	20041223	US 2004-817312	20040401
US 7153824	B2	20061226		
EP 1624893	A2	20060215	EP 2004-749721	20040401

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

BR 2004009229	A	20060328	BR 2004-9229		20040401
CN 1802177	A	20060712	CN 2004-80014503		20040401
JP 2006522151	T	20060928	JP 2006-509679		20040401
NO 2005004890	A	20051021	NO 2005-4890		20051021
IN 2005DN04983	A	20070817	IN 2005-DN4983		20051031
US 2006229288	A1	20061012	US 2006-276459		20060228
PRIORITY APPLN. INFO.:			US 2003-458955P	P	20030401
			US 2003-470434P	P	20030515
			US 2004-540301P	P	20040128
			US 2004-544003P	P	20040212
			US 2004-817312	A1	20040401
			WO 2004-US10346	A	20040401

AB The present invention is directed to methods of increasing oocyte prodn. in a mammal. More specifically, the specification describes methods and compns. for inducing follicular maturation using a PDE inhibitor. The inhibitor may be used alone at high doses. Alternatively, the follicular maturation is achieved by combining a low dose of FSH with the PDE inhibitor treatment.

IT 139145-27-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods for the treatment of infertility with inhibitors of phosphodiesterases (PDE) in conjunction with gonadotropins)

RN 139145-27-0 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



L6 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2003:296061 CAPLUS Full-text
DOCUMENT NUMBER:	138:297701
TITLE:	Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
INVENTOR(S):	Doherty, Paul C., Jr.; Place, Virgil A.; Smith, William L.
PATENT ASSIGNEE(S):	Vivus, Inc., USA
SOURCE:	U.S., 13 pp., Cont.-in-part of U.S. 6,037,346. CODEN: USXXAM
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	7
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6548490	B1	20030415	US 1999-467094	19991210
US 6037346	A	20000314	US 1998-181070	19981027
CA 2394060	A1	20010614	CA 2000-2394060	20001208

WO 2001041807	A2	20010614	WO 2000-US33372		20001208
WO 2001041807	A3	20020214			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
AU 200122566	A	20010618	AU 2001-22566		20001208
EP 1237577	A2	20020911	EP 2000-986297		20001208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
JP 2003516363	T	20030513	JP 2001-543151		20001208
US 2002037828	A1	20020328	US 2001-888250		20010621
US 6403597	B2	20020611			
US 2002004498	A1	20020110	US 2001-938417		20010823
US 2003134861	A1	20030717	US 2003-351198		20030124
AU 2005248938	A1	20060202	AU 2005-248938		20051223
PRIORITY APPLN. INFO.:			US 1997-958816	B2	19971028
			US 1998-181070	A2	19981027
			US 1999-467094	A	19991210
			AU 2001-22566	A3	20001208
			WO 2000-US33372	W	20001208

AB A method is provided for treating erectile dysfunction in a mammalian male individual. The method involves the transmucosal administration of a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, within the context of an effective dosing regimen. Preferred modes of administration include transbuccal, sublingual and transrectal routes. Pharmaceutical formulations and kits are provided as well.

IT 139145-27-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction)

RN 139145-27-0 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:314395 CAPLUS Full-text
DOCUMENT NUMBER: 136:335540
TITLE: Use of PDE V inhibitors for improved fecundity in

mammals

INVENTOR(S): Westbrook, Simon Lempriere; Zanzinger, Johannes Friedrich

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1199070	A2	20020424	EP 2001-308684	20011011
EP 1199070	A3	20040317		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA 2359383	A1	20020420	CA 2001-2359383	20011018
US 2003018036	A1	20030123	US 2001-982445	20011018
US 6548508	B2	20030415		
AU 200181523	A	20020502	AU 2001-81523	20011019
HU 200104406	A2	20020729	HU 2001-4406	20011019
JP 2002220346	A	20020809	JP 2001-322195	20011019
JP 3842104	B2	20061108		
ZA 2001008617	A	20030422	ZA 2001-8617	20011019
NZ 514947	A	20050324	NZ 2001-514947	20011019
US 2003018037	A1	20030123	US 2002-229534	20020827
US 6743799	B2	20040601		
US 2004167095	A1	20040826	US 2004-778866	20040212
AU 2004233509	A1	20041223	AU 2004-233509	20041126

PRIORITY APPLN. INFO.:

GB 2000-25782	A	20001020
US 2000-253338P	P	20001128
US 2001-982445	A1	20011018
AU 2001-81523	A3	20011019
US 2002-229534	A1	20020827

AB The invention relates to the use of a cyclic guanosine 3',5'-monophosphate phosphodiesterase type five (cGMP PDE V) inhibitor for increasing fecundity in a mammal by one or more of (a) promoting the growth of an oocyte, zygote, blastocyst, embryo and/or fetus, (b) increasing the rate or probability of survival of an embryo and/or fetus and (c) increasing the birth weight of a progeny, or for increasing milk productivity. I.v. and tablet formulations are exemplified. Formulations and packs containing the PDE V inhibitors for pharmaceutical or veterinary use are claimed.

IT 139145-27-0
RL: AGR (Agricultural use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of PDE V inhibitors for improved fecundity in mammals)

RN 139145-27-0 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



L6 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:241329 CAPLUS Full-text
DOCUMENT NUMBER: 136:284433
TITLE: Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
INVENTOR(S): Wilson, Leland F.; Doherty, Paul C.; Place, Virgil A.; Smith, William L.; Abdel-Hamid, Abdou Ali Ibrahim Aboubakr
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 467,094.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002037828	A1	20020328	US 2001-888250	20010621
US 6403597	B2	20020611		
US 6037346	A	20000314	US 1998-181070	19981027
US 6548490	B1	20030415	US 1999-467094	19991210
CA 2451152	A1	20030103	CA 2002-2451152	20020325
WO 2003000343	A2	20030103	WO 2002-US9415	20020325
WO 2003000343	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002248712	A1	20030108	AU 2002-248712	20020325
EP 1418896	A2	20040519	EP 2002-717729	20020325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005519851	T	20050707	JP 2003-506984	20020325
AU 2005248938	A1	20060202	AU 2005-248938	20051223

PRIORITY APPLN. INFO.:		
US 1997-958816	B2	19971028
US 1998-181070	A2	19981027
US 1999-467094	A2	19991210
AU 2001-22566	A3	20001208
US 2001-888250	A	20010621
WO 2002-US9415	W	20020325

AB A method is provided for treatment of premature ejaculation by administration of a phosphodiesterase inhibitor, e.g., an inhibitor of a Type III, Type IV, or Type V phosphodiesterase. In a preferred embodiment, administration is on as "as needed" basis, i.e., the drug is administered immediately or several hours prior to sexual activity. Pharmaceutical formulations and packaged kits are also provided. Zaprinast 1.0, mannitol 1.0, microcryst. cellulose 2.0, and magnesium stearate 10 mg are blended in a suitable mixer and then compressed into sublingual tablets. Each sublingual tablet contains 10 mg zaprinast.
IT 139145-27-0

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(administration of phosphodiesterase inhibitors for treatment of premature ejaculation)

RN 139145-27-0 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



L6 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:142493 CAPLUS Full-text

DOCUMENT NUMBER: 136:194255

TITLE: Treatment of the insulin resistance syndrome

INVENTOR(S): Fryburg, David Albert; Gibbs, Earl Michael; Koppiker, Nandan Parmanand

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013798	A2	20020221	WO 2001-IB1428	20010806
WO 2002013798	A3	20030123		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2419033	A1	20020221	CA 2001-2419033	20010806
AU 200176607	A	20020225	AU 2001-76607	20010806
EP 1307183	A2	20030507	EP 2001-954266	20010806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 200300725	A2	20031128	HU 2003-725	20010806
JP 2004506009	T	20040226	JP 2002-518944	20010806
US 2002165237	A1	20021107	US 2001-927525	20010810
CA 2436576	A1	20020808	CA 2002-2436576	20020130
WO 2002060422	A2	20020808	WO 2002-IB315	20020130
WO 2002060422	A3	20021010		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002226633	A1	20020812	AU 2002-226633	20020130
US 2002143015	A1	20021003	US 2002-60788	20020130
US 6683080	B2	20040127		
EP 1355651	A2	20031029	EP 2002-716245	20020130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002006847	A	20040225	BR 2002-6847	20020130
JP 2004527476	T	20040909	JP 2002-560615	20020130
ZA 2003001030	A	20040422	ZA 2003-1030	20030206
US 2003166662	A1	20030904	US 2003-368826	20030219
MX 2003PA06936	A	20031118	MX 2003-PA6936	20030801
PRIORITY APPLN. INFO.:			US 2000-224928P	P 20000811
			GB 2000-30649	A 20001215
			US 2001-266083P	P 20010202
			GB 2001-6465	A 20010315
			GB 2001-6468	A 20010315
			GB 2001-17134	A 20010713
			US 2000-256431P	P 20001218
			US 2001-292506P	P 20010521
			WO 2001-IB1428	W 20010806
			US 2001-927525	B1 20010810
			WO 2002-IB315	W 20020130

AB Use of a selective cGMP PDE5 inhibitor or a pharmaceutical compn. thereof in the preparation of a medicament for the curative, palliative or prophylactic treatment of the insulin resistance syndrome wherein the insulin resistance syndrome means the concomitant existence in a subject of two or more of: dyslipidemia; hypertension; type 2 diabetes mellitus, impaired glucose tolerance (IGT) or a family history of diabetes; hyperuricemia and/or gout; a pro-coagulant state; atherosclerosis; or truncal obesity wherein said use can occur alone or in combination with other agents to treat the insulin resistance syndrome or individual aspects of the insulin resistance syndrome.

IT 139145-27-0
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of insulin resistance syndrome)

RN 139145-27-0 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



L6 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:713125 CAPLUS Full-text

DOCUMENT NUMBER: 135:251965
TITLE: L-Arginine and phosphodiesterase (PDE) inhibitor synergism, and use in the treatment of cardiac pathology and/or erectile dysfunction
INVENTOR(S): Wallace, Arthur W.
PATENT ASSIGNEE(S): The Regents of the University of California, USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070211	A2	20010927	WO 2001-US8863	20010319
WO 2001070211	A3	20010808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6476037	B1	20021105	US 2000-644982	20000323
AU 2001049284	A5	20011003	AU 2001-49284	20010319
US 2003166661	A1	20030904	US 2002-253404	20020923
PRIORITY APPLN. INFO.:			US 2000-644982 A	20000323
			WO 2001-US8863 W	20010319

AB The invention pertains to the discovery that L-arginine and type V phosphodiesterase inhibitors act synergistically to inhibit vasospasm and/or to induce vasodilation. Methods are provided using combinations of L-arginine and type V phosphodiesterase inhibitors in the treatment of cardiac pathologies and/or the treatment of erectile dysfunction.

IT 139145-27-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(arginine and phosphodiesterase type V inhibitor synergism, and use in treatment of cardiac pathol. and/or erectile dysfunction)

RN 139145-27-0 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



L6 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:434902 CAPLUS Full-text

DOCUMENT NUMBER: 135:51053
TITLE: Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
INVENTOR(S): Doherty, Paul C., Jr.; Place, Virgil A.; Smith, William L.
PATENT ASSIGNEE(S): Vivus, Inc., USA
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001041807	A2	20010614	WO 2000-US33372	20001208
WO 2001041807	A3	20020214		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6548490	B1	20030415	US 1999-467094	19991210
CA 2394060	A1	20010614	CA 2000-2394060	20001208
AU 200122566	A	20010618	AU 2001-22566	20001208
EP 1237577	A2	20020911	EP 2000-986297	20001208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003516363	T	20030513	JP 2001-543151	20001208
AU 2005248938	A1	20060202	AU 2005-248938	20051223

PRIORITY APPLN. INFO.:

US 1999-467094	A	19991210
US 1997-958816	B2	19971028
US 1998-181070	A2	19981027
AU 2001-22566	A3	20001208
WO 2000-US33372	W	20001208

AB A method is provided for treating erectile dysfunction in a mammalian male individual. The method involves the transmucosal administration of a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, within the context of an effective dosing regimen. Preferred modes of administration include transbuccal, sublingual and transrectal routes. Pharmaceutical formulations and kits are provided as well. Thus, a buccal dosage form was prepared from 10 g sildenafil citrate and 90 g gelatin. After the mixing was complete, 20 g concentrated glycerin, 10 g lactose and 20 g mannitol were added and the components were mixed until uniform. Aliquot portions (150 mg) of the mixture were compression-molded to provide a buccal dosage unit. Each buccal unit contained 10 mg sildenafil citrate.

IT 139145-27-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transmucosal administration of phosphodiesterase inhibitors for treatment of erectile dysfunction)

RN 139145-27-0 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



L6 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:421073 CAPLUS Full-text
DOCUMENT NUMBER: 133:43291
TITLE: Preparation of (p-chlorophenyl)propanol derivatives
INVENTOR(S): Matsumoto, Hiroo; Kamikawaji, Minako; Horiuchi, Takashi
PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035843	A1	20000622	WO 1999-JP6654	19991129
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2347813	A1	20000622	CA 1999-2347813	19991129
EP 1138660	A1	20011004	EP 1999-973408	19991129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NZ 511022	A	20020628	NZ 1999-511022	19991129
AU 755010	B2	20021128	AU 2000-14114	19991129
TW 538027	B	20030621	TW 1999-88121220	19991203
ZA 2001003328	A	20011025	ZA 2001-3328	20010424
US 6407298	B1	20020618	US 2001-830555	20010504
NO 2001002811	A	20010607	NO 2001-2811	20010607
MX 2001PA05860	A	20010911	MX 2001-PA5860	20010608
PRIORITY APPLN. INFO.:			JP 1998-352529 A	19981211
			WO 1999-JP6654 W	19991129

OTHER SOURCE(S): CASREACT 133:43291

AB A process for the prepn. of 3-(p-chlorophenyl)propanol, characterized by conducting palladium-catalyzed coupling of p-iodochlorobenzene with allyl alc. in the presence of tetramethylammonium chloride and reducing the obtained product; and a process for the preparation of 3-(p-chlorophenyl)propyl bromide, characterized by brominating (p-chlorophenyl)propanol. 3-(p-chlorophenyl)propyl bromide is an intermediate for the preparation of blood platelet aggregation inhibitor.

IT 139145-84-9P

RL: PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (p-chlorophenyl)propanol derivs. as intermediated for blood platelet aggregation inhibitors)

RN 139145-84-9 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:401655 CAPLUS Full-text

DOCUMENT NUMBER: 133:26869

TITLE: Remedial agent for erectile dysfunction

INVENTOR(S): Tanikawa, Keizo; Tsuruzoe, Nobutomo; Shudo, Norimasa; Yamashita, Toru; Ishiwata, Norihisa; Kido, Hideaki; Ebisu, Hajime; Hayashi, Kazutaka; Kubo, Yoshiji; Nakamura, Norifumi

PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan; Yoshitomi Pharmaceutical Industries, Ltd.

SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033845	A1	20000615	WO 1999-JP6693	19991130
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2353956	A1	20000615	CA 1999-2353956	19991130
EP 1157694	A1	20011128	EP 1999-973258	19991130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NZ 512754	A	20021025	NZ 1999-512754	19991130
AU 768825	B2	20040108	AU 2000-14131	19991130
RU 2229885	C2	20040610	RU 2001-118846	19991130
TW 585767	B	20040501	TW 1999-88121327	19991206

NO 2001002616	A	20010807	NO 2001-2616		20010529
NO 321797	B1	20060703			
MX 2001PA05701	A	20010911	MX 2001-PA5701		20010606
ZA 2001005429	A	20020702	ZA 2001-5429		20010702
PRIORITY APPLN. INFO.:			JP 1998-346798	A	19981207
			WO 1999-JP6693	W	19991130

OTHER SOURCE(S): MARPAT 133:26869

AB An erectile dysfunction remedy comprises as the active ingredient a 3(2H)-pyridazinone derivative or a pharmacol. acceptable salt thereof. 4-Bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)- pyridazinone·HCl was tested with dogs.

IT 139145-27-0 139145-84-9 169202-10-2
171661-79-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyridazinone derivs. for treatment of erectile dysfunction)

RN 139145-27-0 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



RN 139145-84-9 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 169202-10-2 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-[(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 171661-79-3 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-[(3-pyridinylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:169373 CAPLUS Full-text
DOCUMENT NUMBER: 132:217154
TITLE: Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
INVENTOR(S): Doherty, Paul C., Jr.; Place, Virgil A.; Smith, William L.
PATENT ASSIGNEE(S): Vivus, Inc., USA
SOURCE: U.S., 13 pp., Cont.-in-part of U.S. Ser. No. 958,816, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6037346	A	20000314	US 1998-181070	19981027
CA 2305394	A1	19990506	CA 1998-2305394	19981028
CA 2305394	C	20061212		

WO 9921558	A2	19990506	WO 1998-US22928		19981028
WO 9921558	A3	20001026			
W: AU, CA, JP					
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
AU 9911254	A	19990517	AU 1999-11254		19981028
AU 734734	B2	20010621			
EP 1027054	A1	20000816	EP 1998-954032		19981028
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
JP 2003525845	T	20030902	JP 2000-517716		19981028
US 6127363	A	20001003	US 1999-437999		19991110
US 6156753	A	20001205	US 1999-437682		19991110
US 6548490	B1	20030415	US 1999-467094		19991210
US 2002037828	A1	20020328	US 2001-888250		20010621
US 6403597	B2	20020611			
US 2002004498	A1	20020110	US 2001-938417		20010823
US 2003134861	A1	20030717	US 2003-351198		20030124
AU 2005248938	A1	20060202	AU 2005-248938		20051223
PRIORITY APPLN. INFO.:			US 1997-958816	B2	19971028
			US 1998-181070	A	19981027
			WO 1998-US22928	W	19981028
			US 1999-467094	A2	19991210
			AU 2001-22566	A3	20001208

AB A method is provided for treating erectile dysfunction. The method involves the local administration of a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof within the context of an effective dosing regimen. A preferred mode of administration is transurethral. Pharmaceutical formulations and kits are provided as well.

IT 139145-27-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(local administration of phosphodiesterase inhibitors in combination with other drugs for treatment of erectile dysfunction)

RN 139145-27-0 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:161135 CAPLUS Full-text

DOCUMENT NUMBER: 132:189694

TITLE: Remedies for spinal canal stenosis

INVENTOR(S): Maruyama, Tomoyuki; Kawamura, Tooru; Akira, Toshiaki; Kido, Hideaki; Nakamura, Norifumi

PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan; Nissan Chemical Industries, Ltd.

SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012091	A1	20000309	WO 1999-JP4690	19990830
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2342198	A1	20000309	CA 1999-2342198	19990830
CA 2342198	C	20070828		
AU 9954456	A	20000321	AU 1999-54456	19990830
EP 1123704	A1	20010816	EP 1999-940567	19990830
EP 1123704	B1	20040804		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
RU 2229297	C2	20040527	RU 2001-108574	19990830
AT 272401	T	20040815	AT 1999-940567	19990830
PT 1123704	T	20041029	PT 1999-940567	19990830
ES 2221421	T3	20041216	ES 1999-940567	19990830
TW 544312	B	20030801	TW 1999-88114903	19990831
US 6369061	B1	20020409	US 2001-786050	20010321
PRIORITY APPLN. INFO.:			JP 1998-246886 A	19980901
			WO 1999-JP4690 W	19990830

OTHER SOURCE(S): MARPAT 132:189694

GI



I

AB This document discloses remedies for spinal canal stenosis contg. pyridazinone compds. represented by general formula I [R1, R2 and R3 are each independently hydrogen or lower alkyl; X is halogeno, cyano or hydrogen; Y is halogeno, trifluoromethyl or hydrogen; and A is optionally hydroxylated C1-C8 alkylene]. Formulations are given.

IT 139145-27-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(remedy for spinal canal stenosis)
RN 139145-27-0 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:303234 CAPLUS Full-text
DOCUMENT NUMBER: 130:332908
TITLE: Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
INVENTOR(S): Doherty, Paul C., Jr.; Place, Virgil A.; Smith, William L.
PATENT ASSIGNEE(S): Vivus, Inc., USA
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9921558	A2	19990506	WO 1998-US22928	19981028
WO 9921558	A3	20001026		
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6037346	A	20000314	US 1998-181070	19981027
CA 2305394	A1	19990506	CA 1998-2305394	19981028
CA 2305394	C	20061212		
AU 9911254	A	19990517	AU 1999-11254	19981028
AU 734734	B2	20010621		
EP 1027054	A1	20000816	EP 1998-954032	19981028
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2003525845	T	20030902	JP 2000-517716	19981028
AU 2005248938	A1	20060202	AU 2005-248938	20051223

PRIORITY APPLN. INFO.:

US 1997-958816	A	19971028
US 1998-181070	A	19981027
WO 1998-US22928	W	19981028
AU 2001-22566	A3	20001208

AB A method is provided for treating erectile dysfunction in a mammalian male individual. The method involves the local administration of a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, within the context of an effective dosing regimen. A preferred mode of administration is transurethral. Pharmaceutical formulations and kits are provided as well.

IT 139145-27-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphodiesterase inhibitor local administration for treatment of erectile dysfunction)

RN 139145-27-0 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



L6 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:184137 CAPLUS Full-text

DOCUMENT NUMBER: 130:227734

TITLE: Neovascularization promoters and neovascularization potentiators

INVENTOR(S): Egi, Yasuhiro; Kido, Hideaki; Hayashi, Kazutaka; Kubo, Yoshiji; Nakamura, Norifumi

PATENT ASSIGNEE(S): Yoshitomi Pharmaceutical Industries, Ltd., Japan; Nissan Chemical Industries, Ltd.

SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9911268	A1	19990311	WO 1998-JP3820	19980826
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2301852	A1	19990311	CA 1998-2301852	19980826
CA 2301852	C	20070710		
AU 9888862	A	19990322	AU 1998-88862	19980826
EP 1025847	A1	20000809	EP 1998-940584	19980826
EP 1025847	B1	20051026		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

AT 307584	T	20051115	AT 1998-940584		19980826
ES 2247716	T3	20060301	ES 1998-940584		19980826
TW 490303	B	20020611	TW 1998-87114142		19980827
US 6284758	B1	20010904	US 2000-486327		20000225
PRIORITY APPLN. INFO.:			JP 1997-232644	A	19970828
			WO 1998-JP3820	W	19980826

OTHER SOURCE(S): MARPAT 130:227734

GI



I

AB The invention relates to neovascularization promoters and neovascularization potentiators, containing as the active ingredient pyridazinone compds. represented by general formula (I) [R1-3 = H or lower alkyl; X = halo, cyano or H : Y = halo, trifluoromeyhl or H; A = (un)substituted C1-8 alkylene] or pharmacol. acceptable salts thereof wherein each symbol is as defined in the specification. The pyridazinone compds. and pharmacol. acceptable salts thereof have the effects of promoting neovascularization and potentiating the drugs having these effects, which makes them useful as neovascularization promoters and neovascularization potentiators.

IT 221105-43-7 221105-44-8

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (neovascularization promoters and neovascularization potentiators)

RN 221105-43-7 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[methyl(3-pyridinylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 221105-44-8 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[methyl(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:585823 CAPLUS Full-text
DOCUMENT NUMBER: 129:193739
TITLE: Compositions for oral administration containing pyridazinone compounds
INVENTOR(S): Iwao, Toru; Seki, Tomoyo; Kondo, Nobuo; Ueda, Yasuo
PATENT ASSIGNEE(S): The Green Cross Corp., Japan; Nissan Chemical Industries, Ltd.
SOURCE: Eur. Pat. Appl., 10 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

EP 860169	A2	19980826	EP 1998-101553	19980129
EP 860169	A3	19990616		
EP 860169	B1	20040728		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 10273440	A	19981013	JP 1998-11315	19980123
TW 482675	B	20020411	TW 1998-87101030	19980126
CA 2228078	A1	19980731	CA 1998-2228078	19980128
CA 2228078	C	20070313		
US 5942249	A	19990824	US 1998-14563	19980128
ES 2224296	T3	20050301	ES 1998-101553	19980129
CN 1194139	A	19980930	CN 1998-106413	19980131
CN 1114408	B	20030716		
HK 1016070	A1	20040116	HK 1999-101104	19990316

PRIORITY APPLN. INFO.: JP 1997-19115 A 19970131

OTHER SOURCE(S): MARPAT 129:193739

AB A compn. for oral administration contains a pyridazinone compd. known to have superior platelet aggregation inhibitory activity and an organic acid. The composition is stable to heat, light, and moisture and provides an improved dissoln., resulting in an enhanced absorption of a pyridazinone compound, preferably 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethylamino)-3(2H)-pyridazinone (I). Tablets were prepared containing I·HCl 10, citric acid 5, lactose 123, hydroxypropyl cellulose 4, Na croscarmellose 7, and Mg stearate 1 mg/each by the wet granulation compression method.

IT 139145-27-0 139145-84-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tablets with improved stability and bioavailability containing pyridazinone compds. and organic acid)

RN 139145-27-0 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



RN 139145-84-9 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L6 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:992456 CAPLUS Full-text
DOCUMENT NUMBER: 124:55968
TITLE: Preparation of pyridazinone derivatives having potent antithrombocytic activity
INVENTOR(S): Tanikawa, Keizo; Matsumoto, Takashi; Matsumoto, Hiroo; Tsuruzoe, Nobutomo; Nakabeppu, Hitoshi
PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9519969	A1	19950727	WO 1995-JP69	19950124
W: AU, CA, CN, CZ, FI, HU, KR, MX, NO, NZ, RO, RU, SI, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2181901	A1	19950727	CA 1995-2181901	19950124
CA 2181901	C	20050913		
AU 9514663	A	19950808	AU 1995-14663	19950124
EP 742211	A1	19961113	EP 1995-906505	19950124
EP 742211	B1	20000510		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, PT, SE				
CN 1138852	A	19961225	CN 1995-191304	19950124
CN 1049892	B	20000301		
HU 74742	A2	19970228	HU 1996-2021	19950124
HU 223963	B1	20050329		
AT 192741	T	20000515	AT 1995-906505	19950124
ES 2147841	T3	20001001	ES 1995-906505	19950124
PT 742211	T	20001031	PT 1995-906505	19950124
JP 07252237	A	19951003	JP 1995-9398	19950125
JP 3666042	B2	20050629		
TW 420665	B	20010201	TW 1995-84100797	19950127
US 5750523	A	19980512	US 1996-676227	19960723
FI 9602957	A	19960724	FI 1996-2957	19960724
FI 112214	B1	20031114		
NO 9603095	A	19960924	NO 1996-3095	19960724
NO 307965	B1	20000626		
US 5856327	A	19990105	US 1997-936600	19970924

PRIORITY APPLN. INFO.:
JP 1994-6541 A 19940125
WO 1995-JP69 W 19950124
US 1996-676227 A3 19960723

OTHER SOURCE(S): CASREACT 124:55968; MARPAT 124:55968
GI



I



II

AB Pyridazinone derivs. represented by general formula [I; R = H, C1-4 alkyl; X = H, Cl, Br; Ar = pyridyl, Ph substituted by OR1 (wherein R1 = H or C1-4 alkyl) and a group selected from H, halo, or C1-4 alkyl or a group selected from OH or C1-4 alkoxy; Y = C1-8 alkylene, one of its C atom being substituted by one OR1 group; Z1, Z2 = H, halo, C1-4 alkyl, OR1 (R1 being as defined above)], which have a broad spectrum of blood platelet aggregation inhibition with high selectivity and reduced side effects (e.g. headache, heaviness of head, hypotension, and palpitation) and are safely used as the active ingredient of a preventive or remedy for various thrombotic diseases, are prepared Thus, a mixture of 1.50 g 4,5-dibromo-6-[3-(4-chlorophenyl)-3-hydroxypropyloxy]-3(2H)-pyridazinone, 1.48 g 3-picolylamine, 45 mL MeOH, and 5 mL H2O was refluxed with stirring overnight to give 1.05 g of the title compound (II; R2 = OH). This compound in vitro inhibited the ADP- and collagen-induced blood platelet aggregation of rabbit platelet rich plasma with IC50 of 0.23 and 0.099 μM, resp. It in vitro showed weaker vasodilating activity (EC50 of 1.3 μM) than the known compound II.HCl (R2 = H) (EC50 of 0.4 μM) in an assay of inhibiting the phenylephrine-induced contraction of rabbit thoracic aorta rings. A tablet and a capsule formulation containing II (R2 = OH) were described.

IT 169202-10-2P 171661-79-3P 171661-81-7P
171661-82-8P 171661-83-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridazinone derivs. having potent antithrombocytic activity)

RN 169202-10-2 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-[(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 171661-79-3 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-[(3-pyridinylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171661-81-7 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-[(3-pyridinylmethyl)amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171661-82-8 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-[(3-pyridinylmethyl)amino]-, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 171661-83-9 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-[(3-pyridinylmethyl)amino]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L6 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:867871 CAPLUS Full-text
DOCUMENT NUMBER: 123:266153
TITLE: Pharmaceutical compositions containing pyridazinone derivatives for prophylaxis and treatment of thromboxane A2-mediated diseases
INVENTOR(S): Ikegawa, Ruriko; Imada, Teruaki; Nakamura, Norifumi; Tanikawa, Keizo; Tsuruzoe, Nobutomo
PATENT ASSIGNEE(S): Green Cross Corp., Japan; Nissan Chemical Industries Ltd.
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9522329	A1	19950824	WO 1995-JP244	19950220
W: AU, CA, CN, CZ, FI, HU, KR, LT, MX, NO, NZ, RU, SI, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
IL 112695	A	19990411	IL 1995-112695	19950219
CA 2183234	A1	19950824	CA 1995-2183234	19950220
CA 2183234	C	20040504		
AU 9517183	A	19950904	AU 1995-17183	19950220
EP 744950	A1	19961204	EP 1995-909122	19950220
EP 744950	B1	20040818		
R: AT, CH, DE, DK, ES, FR, GB, IT, LI, SE				
CN 1141590	A	19970129	CN 1995-191744	19950220
CN 1084620	B	20020515		
AT 273708	T	20040915	AT 1995-909122	19950220
ES 2222464	T3	20050201	ES 1995-909122	19950220
JP 07285869	A	19951031	JP 1995-32300	19950221
JP 3858279	B2	20061213		
ZA 9501470	A	19951207	ZA 1995-1470	19950222
TW 387809	B	20000421	TW 1995-84101784	19950227

US 5798357	A	19980825	US 1996-687604		19960808
NO 9603463	A	19960820	NO 1996-3463		19960820
NO 311490	B1	20011203			
FI 9603264	A	19960821	FI 1996-3264		19960821
FI 116882	B1	20060331			
PRIORITY APPLN. INFO.:			JP 1994-24556	A	19940222
			WO 1995-JP244	W	19950220

OTHER SOURCE(S): MARPAT 123:266153

AB Pharmaceutical compns. for the prophylaxis or treatment of TXA2-mediated diseases, particularly, a TXA2 synthetase inhibitor, comprises a pyridazinone compound (Markush structure given) or a pharmacol. acceptable salt thereof. The amount of 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3- pyridylmethylamino)-3(2H)-pyridazinone.HCl (I) necessary for 50% inhibition of TXA2 synthetase was 0.018 μM. A tablet contained I 10, lactose 20, starch 5, Mg stearate 0.1, and Ca CM-cellulose 7g.

IT 139145-27-0 169202-09-9 169202-10-2
169202-12-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing pyridazinone derivs. for prophylaxis and treatment of thromboxane A2-mediated diseases)

RN 139145-27-0 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



RN 169202-09-9 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-2,2-dimethylpropoxy]-5-[(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 169202-10-2 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-3-hydroxypropoxy]-5-[(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 169202-12-4 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-2-hydroxypropoxy]-5-[(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



L6 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:106307 CAPLUS Full-text
DOCUMENT NUMBER: 116:106307
TITLE: Preparation of pyridazinone derivatives as drugs
INVENTOR(S): Tanikawa, Keizo; Saito, Akira; Matsumoto, Takashi; Sakoda, Ryozo; Tsuruzoe, Nobutomo
PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9116314	A1	19911031	WO 1991-JP517	19910419
W: AU, CA, HU, JP, KR, SU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2053863	A1	19911026	CA 1991-2053863	19910419
CA 2053863	C	19961029		
AU 9176511	A	19911111	AU 1991-76511	19910419
AU 634655	B2	19930225		
EP 482208	A1	19920429	EP 1991-907712	19910419
EP 482208	B1	20000719		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
HU 60253	A2	19920828	HU 1991-3497	19910419

HU 208124	B	19930830			
JP 07107055	B	19951115	JP 1991-507543		19910419
RU 2054004	C1	19960210	RU 1991-5010505		19910419
AT 194835	T	20000815	AT 1991-907712		19910419
ES 2149761	T3	20001116	ES 1991-907712		19910419
ZA 9103134	A	19920429	ZA 1991-3134		19910425
US 5202323	A	19930413	US 1991-768182		19911016
KR 9702876	B1	19970312	KR 1991-71537		19911106
US 5314883	A	19940524	US 1992-994404		19921221
US 5318968	A	19940607	US 1992-994413		19921221
GR 3034331	T3	20001229	GR 2000-402019		20000905
PRIORITY APPLN. INFO.:			JP 1990-109914	A	19900425
			WO 1991-JP517	A	19910419
			US 1991-768182	A3	19911016

OTHER SOURCE(S): MARPAT 116:106307

GI



I



II

AB Pyridazinone derivs. [I; R1 = H, C1-4 linear or branched alkyl, C3-4 alkenyl, etc.; R2 = A1Y1 wherein A1 = C1-12 alkylene, Y1 = CO2H, alkoxycarbonyl, cyano, etc.; R3, R4 = H, C1-3 alkyl; Ar = (substituted) pyridyl, furyl, thienyl, Ph, naphthyl, etc.; X = H, Cl, Br, cyano], useful in treating and preventing thrombotic diseases, congestive failure, hypertension, asthma, allergies, etc., are prepared and formulated. Dichloropyridazinone derivative II (R = Cl) (4.13 g) was refluxed with 6.70 g 3,4-(MeO)2C6H3CH2NH2 in H2O to give 5.28 g amino derivative II [R = 3,4-(MeO)2C6H3CH2NH], which showed IC50 of 0.22 μM against ADP-induced aggregation of platelet-rich plasma in rabbits, vs. 28.0 μM for cilostazol. Also prepared and tested as cardiotonics, vasodilators, and slow-reacting substances of anaphylaxis antagonists were 239 addnl. I.

IT **139145-27-0P 139145-84-9P 139145-87-2P**
139145-88-3P 139145-89-4P 139145-90-7P
139145-99-6P 139146-37-5P 139146-38-6P
139146-52-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as drug)

RN 139145-27-0 CAPLUS

CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]- (CA INDEX NAME)



RN 139145-84-9 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 139145-87-2 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139145-27-0
CMF C19 H18 Br Cl N4 O2



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 139145-88-3 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]-, (2R,3R)-2,3-dihydroxybutanedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139145-27-0

CMF C19 H18 Br Cl N4 O2



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 139145-89-4 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139145-27-0
CMF C19 H18 Br Cl N4 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 139145-90-7 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[(3-pyridinylmethyl)amino]-, ethanedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 139145-27-0
CMF C19 H18 Br Cl N4 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 139145-99-6 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-3-methylbutoxy]-5-[(3-pyridinylmethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 139146-37-5 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)-1-methylpropoxy]-5-[(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)





RN 139146-38-6 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[[(6-chloro-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 139146-52-4 CAPLUS
CN 3(2H)-Pyridazinone, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-[[(6-methoxy-3-pyridinyl)methyl]amino]- (9CI) (CA INDEX NAME)



=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	195.54	395.77

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-35.88	-37.44

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:47:34 ON 19 SEP 2007